title: Impact of adverse drug reaction and predictivity of quality of life status in tuberculosis.
authors.forename: N
authors.initials: N
authors.lastname: Guo
authors.forename: F
authors.initials: F
authors.lastname: Marra
authors.forename: J M
authors.initials: JM
authors.lastname: Fitzgerald
authors.forename: R K
authors.initials: RK
authors.lastname: Elwood
authors.forename: C A
authors.initials: CA
authors.lastname: Marra
mesh_terms: D000995:Antitubercular Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001955:British Columbia; D004977:Ethambutol / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects / Q000627:therapeutic use; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D011718:Pyrazinamide / Q000009:adverse effects / Q000627:therapeutic use; D011788:Quality of Life; D012189:Retrospective Studies; D012293:Rifampin / Q000009:adverse effects / Q000627:therapeutic use; D018434:Sickness Impact Profile; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents; D011718:Pyrazinamide; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin